Literature DB >> 26023045

Validation of the Menopause Rating Scale in Serbian language.

Tatjana Gazibara1, Jelena Dotlic2,3, Nikolina Kovacevic4, Ilma Kurtagic4, Selmina Nurkovic4, Biljana Rancic4, Sanja Radovanovic4, Milan Terzic5,4.   

Abstract

PURPOSE: The study aim was to translate the Menopause Rating Scale (MRS) to Serbian language and assess its validity and reliability in the population of Serbian menopausal women.
METHODS: The study included 200 peri- and postmenopausal women from two Community Health Centers (city center and outskirts) in the Serbian capital-Belgrade. Women filled out general questionnaire (socio-demographics, habits, medical history), the MRS, Short Form-36 questionnaire (SF-36) and Beck's Depression Inventory (BDI). The MRS was translated according to recommended methodology and its psychometric properties (internal consistency, factor analysis, discriminant, construct and criterion validity) were assessed.
RESULTS: The Cronbach's alpha coefficient for the whole scale was 0.884 (psychological α = 0.902, somato-vegetative α = 0.761, urogenital α = 0.734). Values of the CI-TC coefficient for Serbian MRS were adequate for 10 items, proving their suitability in the scale. On factor analysis, we obtained the same 3 factors as in the original scale (73.1 % of variance). Communalities of all items were appropriate (>0.4). There was no common method bias. The MRS total score was correlated positively with BDI score (p = 0.001) and negatively with all SF-36 domains (p = 0.001) except General Health. Based on ROC analysis, MRS scores were more consistent for post- than perimenopausal Serbian women. Similar results of two raters (p > 0.05) implied on adequate translation and reliability of MRS.
CONCLUSION: Serbian version of MRS demonstrated excellent reliability and validity. The MRS in Serbian language can be used in daily clinical work with menopausal women for assessing their symptoms and quality of life.

Entities:  

Keywords:  Menopause; Menopause Rating Scale; Scale validation; Serbia

Mesh:

Year:  2015        PMID: 26023045     DOI: 10.1007/s00404-015-3743-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  6 in total

1.  Citalopram improves vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial.

Authors:  Patricia Loranca-Moreno; Juan Moises Ocampo-Godínez; Alan Rios-Espinosa; Magdalena Cruz-Luna; Carolina Garmendia-Gallardo; Merle Yasmin Hernández-Castañón; Verónica Yazmin Hernández-Hernández; Paula Mariana Sánchez-Tinoco; Alma Bajonero-Domínguez; Jael Adrián Vergara Lope-Núñez; Marco Antonio Álvarez-Pérez; José Luis González-Quiroz
Journal:  Arch Gynecol Obstet       Date:  2022-08-23       Impact factor: 2.493

Review 2.  Review of menopausal palpitations measures.

Authors:  Ying Sheng; Janet S Carpenter; Charles D Elomba; Jennifer S Alwine; Min Yue; Caitlin A Pike; Chen X Chen; James E Tisdale
Journal:  Womens Midlife Health       Date:  2021-05-31

3.  The Persian Version of Menopause Rating Scale (MRS): A Psychometric Study.

Authors:  Hamid Allahverdipour; Mohammad Asghari Jafarabadi; Andrea Burri; Zeinab Javadivala
Journal:  Int J Womens Health       Date:  2020-06-25

4.  The psychometric properties of the Persian menopause rating scale.

Authors:  Leila Jahangiry; Robabeh Parviz; Mojgan Mirghafourvand; Maryam Khazaee-Pool; Koen Ponnet
Journal:  BMC Womens Health       Date:  2020-08-12       Impact factor: 2.809

5.  Cross cultural adaptation and analysis of psychometric properties of Sinhala version of Menopause Rating Scale.

Authors:  Nirmala Rathnayake; Janaka Lenora; Gayani Alwis; Sarath Lekamwasam
Journal:  Health Qual Life Outcomes       Date:  2018-08-06       Impact factor: 3.186

6.  The relationship between management strategies for menopausal symptoms and women's decision making styles during menopausal transition.

Authors:  Narjes Bahri; Moosa Sajjadi; Leila Sadeghmoghadam
Journal:  Prz Menopauzalny       Date:  2019-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.